[PDF][PDF] Galectin‐9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: a longitudinal cohort study and multicohort validation

J Wienke, F Bellutti Enders, J Lim… - Arthritis & …, 2019 - Wiley Online Library
Objective Objective evaluation of disease activity is challenging in patients with juvenile
dermatomyositis (DM) due to a lack of reliable biomarkers, but it is crucial to avoid both …

Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response

B Lerkvaleekul, SR Veldkamp, MM Van Der Wal… - …, 2022 - academic.oup.com
Objective JDM is a rare chronic immune-mediated inflammatory disease with a predominant
role for type I IFN responses. We aimed to determine the potential of Siglec-1 expression on …

[HTML][HTML] Dutch juvenile idiopathic arthritis patients, carers and clinicians create a research agenda together following the James Lind Alliance method: a study protocol

CG Schoemaker, W Armbrust, JF Swart… - Pediatric …, 2018 - Springer
Abstract Background Research on Juvenile Idiopathic Arthritis (JIA) should support patients,
caregivers/parents (carers) and clinicians to make important decisions in the consulting …

Identification of an amino acid motif in HLA–DR β1 that distinguishes uveitis in patients with juvenile idiopathic arthritis

AMJW Haasnoot, MW Schilham… - Arthritis & …, 2018 - Wiley Online Library
Objective Uveitis is a visually debilitating disorder that affects up to 30% of children with the
most common forms of juvenile idiopathic arthritis (JIA). The disease mechanisms …

[HTML][HTML] Clinical Symptoms, Laboratory Parameters and Long-Term Follow-up in a National DADA2 Cohort

MVE Andriessen, GE Legger, RGM Bredius… - Journal of clinical …, 2023 - Springer
Deficiency of adenosine deaminase-2 (DADA2) is an autosomal recessive autoinflammatory
disease with an extremely variable disease presentation. This paper provides a …

Update on the treatment of nonsystemic juvenile idiopathic arthritis including treatment-to-target: is (drug-free) inactive disease already possible?

IR Klein-Wieringa, DMC Brinkman… - Current Opinion in …, 2020 - journals.lww.com
Remission can be achieved and sustained in (some) JIA patients, regardless of initial
treatment. Cornerstone principles in the management of nonsystemic JIA treatment are early …

[PDF][PDF] Endothelial and inflammation biomarker profiles at diagnosis reflecting clinical heterogeneity and serving as a prognostic tool for treatment response in two …

J Wienke, LM Pachman, GA Morgan… - Arthritis & …, 2020 - Wiley Online Library
Objective Juvenile dermatomyositis (DM) is a heterogeneous systemic immune‐mediated
vasculopathy. This study was undertaken to 1) identify inflammation/endothelial dysfunction …

Nailfold capillary abnormalities in childhood-onset systemic lupus erythematosus: a cross-sectional study compared with healthy controls

D Schonenberg-Meinema, SC Bergkamp… - Lupus, 2021 - journals.sagepub.com
Objectives For selection of high-risk systemic lupus erythematosus (SLE) patients it is
necessary to obtain indicators of disease severity that predict disease damage. As in …

Gene signature fingerprints stratify SLE patients in groups with similar biological disease profiles: a multicentre longitudinal study

MJ Wahadat, D Schonenberg-Meinema… - …, 2022 - academic.oup.com
Objectives Clinical phenotyping and predicting treatment responses in SLE patients is
challenging. Extensive blood transcriptional profiling has identified various gene modules …

MRP8/14 and neutrophil elastase for predicting treatment response and occurrence of flare in patients with juvenile idiopathic arthritis

AM Barendregt, SR Veldkamp… - …, 2020 - academic.oup.com
Objective To study two neutrophil activation markers, myeloid-related protein (MRP) 8/14
and neutrophil elastase (NE), for their ability to predict treatment response and flare in …